Physician profile
David A Snyder
NPI 1487653176
$13,279.87
in general payments reported to CMS, 2019-2025
67 companies · $2,789 in 2025
The $2,789 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $320 · 2021: $1,248 · 2022: $1,991 · 2023: $3,117 · 2024: $3,192 · 2025: $2,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,963 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,963.38 |
| Education | $134.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,339.86 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,068.02 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $867.18 | 2019-2025 | Darzalex, Talvey, Erleada |
| E.R. Squibb & Sons, L.L.C. | $770.61 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $640.11 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $632.46 | 2020-2025 | Cabometyx |
| Incyte Corporation | $493.25 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Seagen INC. | $439.39 | 2020-2023 | Adcetris, Padcev, Tukysa |
| Pfizer INC. | $380.78 | 2019-2025 | |
| Eisai INC. | $354.35 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $346.42 | 2019-2025 | Alunbrig, Fruzaqla, Iclusig |
| Abbvie INC. | $345.15 | 2021-2025 | Venclexta |
| Genentech USA, INC. | $339.83 | 2019-2025 | Alecensa, Rozlytrek, Polivy |
| Celgene Corporation | $335.67 | 2019-2025 | Reblozyl, Opdualag |
| Genzyme Corporation | $320.16 | 2019-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $298.32 | 2020-2023 | Nplate, Vectibix, Xgeva |
| Abbott Laboratories | $275.06 | 2023 | Proclaim |
| Daiichi Sankyo INC. | $247.34 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Jazz Pharmaceuticals INC. | $241.72 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $241.42 | 2021-2025 | |
| Beigene USA, INC. | $241.31 | 2021-2025 | Brukinsa |
| Kite Pharma, INC. | $221.59 | 2022-2025 | Yescarta |
| Lilly USA, LLC | $219.55 | 2020-2024 | Retevmo, Jaypirca, Verzenio |
| Gilead Sciences, INC. | $158.47 | 2019-2024 | |
| Array Biopharma INC | $153.78 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Emd Serono, INC. | $151.74 | 2021-2025 | Bavencio |
| Stemline Therapeutics INC. | $151.74 | 2024-2025 | Orserdu |
| Puma Biotechnology, INC. | $144.11 | 2020-2025 | Nerlynx |
| Karyopharm Therapeutics INC. | $122.48 | 2022-2025 | Xpovio |
| Taiho Oncology, INC. | $117.59 | 2021-2024 | |
| Glaxosmithkline, LLC. | $109.53 | 2020-2025 | Ojjaara |
| Blueprint Medicines Corporation | $98.46 | 2021-2024 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $92.73 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Servier Pharmaceuticals LLC | $83.06 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $77.89 | 2022-2024 | Ultomiris |
| Genmab U.S., INC. | $76.91 | 2023-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $76.86 | 2021-2023 | Imbruvica |
| Astellas Pharma US INC | $61.85 | 2019-2024 | Xtandi |
| Sanofi-Aventis U.S. LLC | $59.21 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $57.08 | 2023-2024 | Libtayo |
| Springworks Therapeutics, INC. | $54.48 | 2024-2025 | Ogsiveo |
| Sobi, INC | $52.69 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $51.51 | 2022-2025 | Clonoseq |
| G1 Therapeutics, INC. | $50.45 | 2021-2022 | |
| Geron Corporation | $45.03 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $43.01 | 2023-2025 | Zoladex |
| Beone Medicines USA, INC. | $41.51 | 2025 | Tevimbra, Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.82 | 2025 | |
| Pharmaessentia USA Corporation | $33.54 | 2022-2024 | Besremi |
| Mirati Therapeutics, INC. | $33.41 | 2023 | Krazati |
| Cti Biopharma Corp. | $32.89 | 2022-2023 | Vonjo |
| Kyowa Kirin, INC. | $31.92 | 2021-2023 | Poteligeo |
| Roche Diagnostics Corporation | $30.25 | 2019 | |
| Dendreon Pharmaceuticals LLC | $30.02 | 2024 | Provenge |
| Pharmacosmos Therapeutics INC. | $28.46 | 2023-2025 | Monoferric |
| Tempus Ai, INC | $27.43 | 2024 | |
| Pharming Healthcare, INC. | $22.35 | 2023 | Ruconest |
| Deciphera Pharmaceuticals INC. | $21.94 | 2024 | Qinlock |
| Cycle Pharmaceuticals INC | $21.60 | 2025 | Phyrago |
| Nuvation Bio INC. | $21.40 | 2025 | Ibtrozi |
| Dova Pharmaceuticals | $19.46 | 2019 | |
| Legend Biotech USA INC. | $18.36 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $17.88 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $16.93 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.41 | 2019 | |
| Heron Therapeutics, INC. | $15.20 | 2022 | |
| Mylan Institutional INC. | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.